Anna Fuji Rahimah
Brawijaya Cardiovascular Research Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Malang

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

The Effect of Bisoprolol on Heart Failure Preserved Ejection Fraction/HFpEF Patient’s Quality of Life Ayu Asri Devi Adityawati; Anna Fuji Rahimah; Mohammad Saifur Rohman; Setyasih Anjarwani; Djanggan Sargowo
Heart Science Journal Vol 2, No 4 (2021): Management of Thrombosis in Covid-19 Patient with Cardiovascular Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2021.002.04.6

Abstract

Global Publich Health Burden of Heart Failure reported the growing prevalence of heart failure from 26 million people affected in 2017 to 64.3 million affected in 2020 worldwide with half of the case classified as heart failure preserved ejection fraction/HFpEF. It is well known that someone who have been diagnosed with heart failure will have a poorer quality of life/QoL. β-blocker is a heart rate lowering agent with a potency to improve the patient’s clinical outcome. One clinical outcome that should always be evaluated and become the main goal of the therapy is QoL of the patient. This study aimed to observe and evaluate the effect of Bisoprolol, a type of β-blocker, in the improvement of HFpEF patient’s QoL. This study is a retrospective cohort following HFpEF patients who received β-blocker and HFpEF patients who did not received β-blocker in a span of 6 months. The study participant selected by purposive sampling method. Our study found that from all HFpEF patients who received β-blocker 86 patients had a good QoL, 16 patients had a Mod QoL, and 2 patients had a poor QoL (p=0.000). Mean physical score in the patient who did not received β-blocker was 13.84±11.01 while the mean score of the patient who received β-blocker was 5.94±4.95 (p=0.000). Mean emotional score in the patient who did not received β-blocker was 6.02±6.61 while the mean score of patient who received β-blocker was 1.83±2.16 (p=0.000). We conclude that the use of Bisoprolol could improve the HFpEF patient’s QoL evaluated by total score, physical score, and emotional score.   
Cardiomyopathy in Pregnancy: A Review Literature Ayu Asri Devi Adityawati; Anna Fuji Rahimah; Heny Martini; Cholid Tri Tjahjono
Heart Science Journal Vol 2, No 1 (2021): How to Diagnose Heart Failure and Deal with The Treatment Complexity
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2021.002.01.03

Abstract

AbstractBACKGROUND: Pregnancy is an experience that many women can achieve. Pregnancy is generally well tolerated in asymptomatic patients with cardiomyopathies but in restrictive form cardiomyopathy, pregnancy cannot be tolerated because of poor prognosis. Prior cardiac events, poor functional class (New York Heart Association class III or IV), or advanced left ventricular systolic dysfunction are present, the risk of maternal cardiac complications during pregnancy are markedly increased. Worsening of the clinical condition can occur during pregnancy, despite intensive medical treatment. Although the incident of cardiovascular disease is present 0.5-4% in developed countries, our knowledge about various of cardiomyopathy and pregnancy should be updateable.CONCLUSION: Our literature provide three types of cardiomyopathy in pregnancy with an example condition for each type that relevant during pregnancy. Peripartum cardiomyopathy is the most common form of cardiomyopathy occured in pregnancy therefore a thorough review is needed to give best outcome for pregnancy. Arryhtmia is the commonnest form in hypertrophic cardiomyopathy which need to be regularly monitored and measure should be taken if the arryhtmia is life threatening for mother and the child. Cardiac amyloidosis is the common form of restrictive cardiomyopathy in pregnancy.Keywords: Pregnancy; Cardiomyopathy; Peri Partum Cardio Myopathy (PPCM), Pregnancy, Heart Failure 
Atherosclerosis Early Detection In Type 1 Diabetes Mellitus Seprian Widasmara; Novi Kurnianingsih; Mohammad Saifur Rohman; Anna Fuji Rahimah
Heart Science Journal Vol 3, No 3 (2022): Cardiovascular Disease in Young Adulthood: Who, When, and How to Screen?
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2022.003.03.3

Abstract

Atherosclerosis continues to be a significant consequence in type I diabetes mellitus (T1DM). Cardiovascular disease, caused by accelerated atherosclerosis, is the leading cause of illness and often premature death in patients with T1DM. Risk management is critical. Patients with T1DM who are at an increased risk include those who are less than 10 years old at the time of diagnosis, have a longer history of diabetes, have microvascular problems, or have several risk factors. It is frequently difficult to evaluate vascular hazard and the degree of atherosclerosis on an individualized level, especially early on.